Ex Vivo Test of New Stroke Treatment Using Magnetic Nanorobots
Steered t-PA Delivery for Thrombolysis Test Using Magnetic Swarming Nanorobots on Human Placenta as an ex Vivo Model of Human Cerebral Vascular System
Tissue plasminogen activator (tPA) is the FDA approved thrombolytic drug for patients with acute ischemic stroke. While transcatheter endovascular therapy is widely accepted as an effective method for targeted blood vessels via a catheter to elicit ischemic necrosis.
To improve targeting accuracy administrated tPA and avoiding collateral tissue damage, we developed a magnetic nanorobotic system to active system to active intravenous delivery of tPA for targeted thrombus removal. Here human placenta will be used as an ex vivo model for human cerebral vascular system in our ex vivo thrombolysis study. Our magnetic nanorobotic system encapsulated with tPA overcomes the limitations of passive thrombolytic therapy with tPA alone and will be a promising approach for the treatment of ischemic stroke and other thrombotic diseases
研究概览
地位
条件
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
New Territories
-
Shatin、New Territories、香港
- 主动，不招人
- Advanced Nanomaterials & Microrobotics Laboratory, Room 202, William M.W Mong Engineering Building, CUHK and Room 508, Li Ka Shing Medical Sciences Building, Prince of Wales Hospital
-
Shatin、New Territories、香港
- 招聘中
- Department of Obstetrics and Gynaecology, Prince of Wales Hospital
-
接触：
- Pui Wah Chung, Doctor
- 电话号码：(852) 35051537
- 邮箱：jacquelinechung@cuhk.edu.hk
-
首席研究员：
- Pui Wah Chung, Doctor
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
- Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth with natural delivery or caesarean sections after 37-42 weeks of gestation.
- Healthy singleton pregnancy.
- Participant able to give voluntary, written, informed consent to participate in the study.
描述
Inclusion Criteria:
- Healthy pregnant women at 20-45 years of age of any ethic origin, giving childbirth with natural delivery or caesarean sections after 37-42 weeks of gestation.
- Healthy singleton pregnancy.
- Participant able to give voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Abnormal prenatal development (e.g intrauterine growth restriction)
- Early preterm birth < 37 weeks
- Verbal Confirmation of hypercholesterolemia
- Family history of stroke or vascular disease
- Type I or Type II diabetes and gestational diabetes
- Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative.
- Clinically significant abnormal laboratory results at screening.
- Any other active or unstable medical condition.
- History of liver disease.
- History of hypertension (including pre-eclampsia)
学习计划
研究是如何设计的？
设计细节
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Thrombolysis performance
大体时间：1 -2 hours
|
Size of thrombus by angiography, mm
|
1 -2 hours
|
|
Time for recanalization
大体时间：1 -2 hours
|
Time for recanalization of occluded vessels, mins
|
1 -2 hours
|
|
Damage to vessels
大体时间：1 -2 hours
|
Histological damage evaluation.
The vessels are sectioned and stained with H&E stain
|
1 -2 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Stability of magnetic nanorobots
大体时间：1 - 2 hours
|
Controllability of the magnetic nanorobots.
The loss in mass of nanorobots after magetic navigation in blood vessels is measured.
|
1 - 2 hours
|
|
Dosage requirement
大体时间：1 - 2 hours
|
Dosage requirement of nanorobots and thus t-PA, mg
|
1 - 2 hours
|
|
Distribution of administrated nanorobots
大体时间：1 - 2 hours
|
The distribution of administrated nanorobots.
The position of nanorobots is tracked by MRI.
|
1 - 2 hours
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.